What is Difelikefalin?
Difelikefalin (brand name KORSUVA in the US, KAPRUVIA in Europe; development code CR845) is a synthetic, peripherally-restricted, all-D-amino-acid tetrapeptide kappa-opioid receptor (KOR) agonist developed by Cara Therapeutics. It was approved by the FDA in August 2021 for moderate-to-severe pruritus associated with chronic kidney disease in adults on hemodialysis — the first systemic peptide therapy ever approved for any pruritus indication.
Chronic kidney disease-associated pruritus (CKD-aP) affects 20–40% of dialysis patients and severely impacts sleep, mood, and quality of life. Until difelikefalin, treatment options were limited to gabapentin, antihistamines, and topical agents — none specifically targeting the underlying neural mechanism.
Mechanism of Action
- Selective kappa-opioid receptor agonism — difelikefalin activates KOR with high selectivity over mu-opioid receptors (MOR) and delta-opioid receptors (DOR)
- Peripherally restricted — its tetrapeptide structure with multiple charged residues prevents passage across the blood-brain barrier, so it does not produce the dysphoria, sedation, or central side effects that have limited classical KOR agonists
- Anti-pruritic and anti-inflammatory — KOR activation on peripheral sensory neurons and immune cells suppresses both itch signaling and skin/mucosal inflammation
- Non-addictive — does not activate MOR-mediated reward circuits
Endogenous KOR signaling is part of the body's natural pruritus-suppressing system. In CKD-aP, this signaling appears insufficient relative to elevated mu-opioid tone and immune activation; difelikefalin restores KOR activity at peripheral sites.
Clinical Evidence — KALM-1 and KALM-2
The pivotal Phase 3 KALM-1 (NCT03422653) and KALM-2 trials (Lancet 2020 / NEJM 2020):
- ~850 hemodialysis patients with moderate-to-severe pruritus randomized to IV difelikefalin or placebo three times per week (post-dialysis)
- Primary endpoint (≥3-point improvement in WI-NRS itch score at week 12): ~50% on difelikefalin vs ~30% placebo (p<0.001)
- Improvements in quality-of-life and sleep scores
- Sustained effect through 52 weeks of open-label extension
Approval History
- August 23, 2021 — FDA approval (IV form) for adults on hemodialysis
- April 2022 — EMA approval (Kapruvia)
An oral formulation has been studied for non-dialysis pruritus indications (notch-related itch, atopic dermatitis, primary biliary cholangitis) but has not yet been approved.
Place in Therapy
Difelikefalin is administered as an IV bolus at the end of each hemodialysis session, three times per week. This dialysis-clinic dosing schedule eliminates adherence concerns and ties dosing to existing patient routines. It has become a standard option for moderate-to-severe CKD-aP that fails first-line therapies.
Safety Profile
The most common adverse events are diarrhea, dizziness, and nausea — generally mild. Notably, difelikefalin does not produce respiratory depression, dysphoria, or addiction potential characteristic of mu-opioid drugs. Because of its peripheral restriction, central nervous system side effects from CNS-penetrant KOR agonists (sedation, dysphoria, hallucinations) are largely absent at therapeutic doses.
Why It Matters
Difelikefalin is one of the cleanest demonstrations of how peptide chemistry can be used to spatially restrict pharmacology — a non-addictive opioid analgesic/antipruritic that works peripherally without crossing into the brain. The same design principle is being explored for chronic pain, post-operative analgesia, and inflammatory itch indications.